Trial Profile
PHASE 3B, OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE PRACTICABILITY AND TOLERABILITY OF SWITCHING SUBJECTS OVERNIGHT FROM PRAMIPEXOLE OR ROPINIROLE TO ROTIGOTINE TRANSDERMAL PATCH AND ITS EFFECT ON SYMPTOMS IN SUBJECTS WITH IDIOPATHIC RESTLESS LEGS SYNDROME
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2016
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Schwarz BioSciences
- 23 Aug 2011 New trial record